A common missense variant in BRCA2 predisposes to early onset breast cancer by Górski, Bohdan et al.
Open Access
Available online http://breast-cancer-research.com/content/7/6/R1023
R1023
Vol 7 No 6 Research article
A common missense variant in BRCA2 predisposes to early onset 
breast cancer
Bohdan Górski1, Steven A Narod2 and Jan Lubiński1
1Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
2Centre for Research on Women's Health, University of Toronto, Canada
Corresponding author: Steven A Narod, steven.narod@sw.ca
Received: 17 Mar 2005 Revisions requested: 15 Apr 2005 Revisions received: 20 Sep 2005 Accepted: 28 Sep 2005 Published: 24 Oct 2005
Breast Cancer Research 2005, 7:R1023-R1027 (DOI 10.1186/bcr1338)
This article is online at: http://breast-cancer-research.com/content/7/6/R1023
© 2005 Górski et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Mutations in the BRCA2 gene are one of the two
major causes of hereditary breast cancer. Protein-truncating
mutations of BRCA2 are usually deleterious and increase the
risk of breast cancer up to 80% over a lifetime. A few missense
mutations in BRCA2  are believed to have a similarly high
penetrance, apart from more common neutral polymorphisms. It
is often difficult to classify a particular sequence variant as a
mutation or a polymorphism. For a deleterious variant, one would
expect a greater allele frequency in breast cancer cases than in
ethnic-matched controls. In contrast, neutral polymorphic
variants should be equally frequent in the two groups.
Methods We genotyped 3,241 cases of breast cancer
diagnosed at under 51 years of age, unselected for family
history, from 18 hospitals throughout Poland and 2,791 ethnic-
matched controls for a single BRCA2 C5972T variant.
Results The variant was present in approximately 6% of the
Polish population. In the study, 13 women (11 cases and two
controls (OR = 4.7; p = 0.02)) were homozygous for the variant
allele. The overall odds ratio for breast cancer in women with a
single copy of the BRCA2 C5972T variant was 1.1 (p = 0.7);
however, the effect was significant for patients diagnosed at or
before age 40 (OR = 1.4; p = 0.04). We reviewed the
association between the BRCA2 variant in different histologic
subgroups and found the effect most pronounced in women
who had ductal carcinoma in situ (DCIS) with micro-invasion
(OR = 2.8; p < 0.0001).
Conclusion The BRCA2 C5972T allele is a common variant in
Poland that increases the risk of DCIS with micro-invasion. The
homozygous state is rare but increases the risk of breast cancer
five-fold.
Introduction
There are several approaches to identifying low-penetrance
candidate genes for breast cancer. In one approach, it is
assumed that missense variants of genes for which truncating
mutations are clearly pathogenic might also be deleterious. If
the missense allele demonstrates high penetrance (i.e. like
truncating mutations), then it will be relatively straightforward
to establish the association when allele frequency is high. If the
penetrance of the missense variant is low, however, then the
association may be missed if only a small number of cancers
is studied and the variant may falsely be classified as a neutral
polymorphism. We are in the process of establishing a large
database of breast cancer cases and ethnic-matched controls
in order to evaluate the pathogenicity of the common founder
alleles of the most important cancer susceptibility genes. Sev-
eral deleterious founder alleles have been identified in
BRCA1, but to date, no founder mutation in BRCA2 has been
identified [1-3]. There are a few common variant alleles in
BRCA2 in Poland; one of these (C5972T) changes the amino
acid sequence of BRCA2 from threonine to methionine at
codon 1915. It lies within the range of the BRC encoded by
exon 11 that are thought to be involved in binding to RAD51
[4]. We sought to determine whether this common missense
BRCA2 variant plays a role in breast cancer susceptibility.
Materials and methods
Study subjects
The study population included prospectively ascertained
cases of invasive breast cancer diagnosed at 50 years of age
or less at 18 treatment centers throughout Poland between
DCIS = ductal carcinoma in situ; LOH = loss of heterozygosity; OR = odds ratio; RFLP-PCR = restriction fragment length polymorphism polymerase 
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1997 and 2003. Invitation to participate was delivered during
hospital stay or by mail. During the interview, the goals of the
study were explained, informed consent was obtained, genetic
counseling was offered, and a blood sample was taken for
DNA analysis. A detailed family history of cancer was taken
(first-, second-, and third-degree relatives included) and a risk
factor questionnaire was completed. A total of 4,778 cases of
early onset invasive breast cancer were identified at the 18
participating centers during the study period. Of these, 3,627
women (76%) accepted to participate and provided a blood
sample for DNA analyses, 114 died, and 16 refused to partic-
ipate. The medical record and pathology report were reviewed.
In the end, we had DNA available for genotyping from 3,241
patients.
Controls
Two control groups were combined. The first group consisted
of 2,000 unselected neonates from ten hospitals throughout
Poland born in 2003 and 2004. Samples of cord blood were
forwarded to the study center in Szczecin. The second control
group consisted of 1,000 adults from the region of Szczecin
unselected for cancer family history, sex, or age. We geno-
typed 2,791 controls for the C5972T allele, 1,993 neonates
and 798 adults. To ensure comparability of the control groups,
C5729T allele frequencies were computed separately for the
adult and neonatal control groups and compared. The study
protocol was approved by the ethics committee of the Pomer-
anian Medical University.
Laboratory methods
All experiments were performed at the Department of Genet-
ics and Pathology, Pomeranian Medical University, Szczecin,
Poland.
DNA isolation
DNA samples were obtained from peripheral blood of adults or
from cord blood of neonates using the non-enzymatic rapid
method as described previously [5].
Analysis of the C5972T variant
The C5972T variant (Thr1915Met) was analyzed by restriction
fragment length polymorphism PCR using b5972F (5'-CTC
TCT AGA TAA TGA TGA ATG ATG CA) and b5972R (5'-
CCA AAC TAA CAT CAC AAG GTG) primers. The forward
primer introduces an artificial restriction site for the Mph1103I
enzyme (Fermentas, St. Leon-Rot, Germany)
PCR products were digested in mutation positive cases. PCR
products were separated in 3% agarose gel and visualized in
ultraviolet light. For positive cases with RFLP-PCR (cleaved by
Mph1103I), a DNA sample was sequenced to confirm the
presence of the mutation. Additionally, 72 randomly selected
samples negative with RFLP-PCR for the C5972T variant
were sequenced. The results of RFLP-PCR and of direct DNA
sequencing were 100% concordant.
DNA sequencing
A fragment of BRCA2 exon 11 was amplified by PCR using
b5972F/b5972R primers. The purified PCR products were
sequenced directly with a BigDye Terminator v3.0 DNA
Sequencing Kit (Perkin Elmer, Foster City, CA, USA) and the
same reverse primer used previously for the amplification of
exon 11 of the BRCA2 gene. Products of sequencing reac-
tions were separated and analysed on the ABI 377 DNA
Sequencer (Perkin Elmer).
BRCA1 testing
All breast cancer patients were tested as described previously
[4] for three mutations (5382insC, C61G, 4153delA) repre-
senting 80% to 90% of all high-risk BRCA1  changes in
Poland.
Statistical analysis
Statistical analysis included a comparison of the prevalence of
the C5972T allele in cases and controls. Odds ratios (ORs)
were generated from two-by-two tables and statistical signifi-
cance was assessed with the chi-square test. BRCA2 nucle-
otides were identified according to the GeneBank U43746
sequence.
Results
The C5972T variant was detected in 8.3% of unselected
breast cancer patients diagnosed at age 40 years or below, in
5.7% of cases diagnosed from age 41 to 50 years, and in
5.8% of Polish controls. The overall OR for breast cancer with
a C5972T mutation was 1.1 (95% CI: 0.8–1.3); however, in
women less than 40 years old the OR was 1.4 (95% CI: 1.0 –
1.9) (Table 1).
We found 13 C5972T homozygotes (11 patients and 2 con-
trols). The OR associated with the homozygous state was 4.7
(95% CI: 1.1 to 21.4). Among 11 cases of breast cancer diag-
nosed in homozygotes, 10 were diagnosed between ages 40
and 50 years. The 11 homozygotes had predominantly intra-
ductal (ductal carcinoma in situ (DCIS) with micro-invasion, 4
cases), ductal G3 (4 cases), lobular (2 cases), and ductal G2
(1 case) cancers. None of the first- or second-degree relatives
of the homozygotes were diagnosed with breast or ovarian
cancer.
We then explored the characteristics of the breast cancers
that were identified in women with the BRCA2 C5972T allele
(Table 2) and compared them with tumors in women without
the predisposing allele (women with BRCA1 mutations were
excluded from all comparisons and women who received pre-
operative chemotherapy were excluded from the histological
comparisons). Women with the BRCA2 variant were more
likely to have bilateral cancer (5% versus 3%) or multifocal
cancer (30% versus 23%) but these differences were not sta-
tistically significant. However, a significant effect was
observed with intraductal cancer. Among the 5972C/TAvailable online http://breast-cancer-research.com/content/7/6/R1023
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heterozygotes, 18 of 103 tumors were predominantly intra-
ductal (17%), compared to 7% in 5972C/C breast cancer
patients (OR = 2.82; p ≤ 0.0001; 95% CI: 1.6–4.8). A heter-
ozygous BRCA2 variant was present in 13% of the women
with predominantly intraductal cancer. Compared to the pop-
ulation controls, the OR for intraductal cancer given a (hetero-
zygous) form of BRCA2 variant was 2.5 (p = 0.0005; 95% CI:
1.5–4.1). For women under 40 years old, the association was
stronger (OR = 4.1; p = 0.006; 95% CI: 1.2–8.3).
Discussion
The C5972T allele of the BRCA2 gene appears to be over-
represented in women with early onset breast cancer in
Poland compared to controls. Although the effect was modest
in the overall data set, it was stronger for women who had pre-
dominantly intraductal breast cancer and for women who were
homozygous for the variant allele. Existing reports on the
C5972T variant do not record any case of homozygote TT
genotypes [6,7]. It is of interest that the heterozygote state
was associated with early onset breast cancer and the
homozygote state with later onset cancer (above 40 years of
age). To our knowledge, this has not been seen before and
there is no compelling explanation; however, we believe that
the sizes of these subgroups are small and require confirma-
tion in other studies.
Our study population consisted of DCIS cases with a micro-
invasive component only. To our knowledge, this is the first
genetic association reported for intraductal cancer with micro-
invasion. Our data set did not include cases of DCIS alone and
we were unable to assess the effect of the BRCA2 C5972T
allele in women with predominantly invasive cancer and asso-
ciated DCIS. These topics will be the focus of future studies.
We did not see other pathological features that distinguished
BRCA2-associated tumors from tumors in non-carriers. This
situation is not different from that described for BRCA2 carri-
ers in general [8-10].
Several previous studies have shown that DCIS is a character-
istic feature of cancers in BRCA2 carriers [11-14]. In the case
of BRCA2-associated breast cancers, it appears that loss of
heterozygosity (LOH) occurs as a means of silencing the sec-
Table 1
Frequencies of the BRCA2 C5972T variant allele in breast cancer patients and controls
Variant Controls Cases Odds ratio p-value 95% CI
All subjects
CC 2,630 3,039 1.0
CT 159 191 1.0 0.74 [0.8–1.3 ]
TT 2 11 4.8 0.02 [1.1–21.4]
CT+TT 161 202 1.1 0.45 [0.9–1.3 ]
Total 2,791 3,241
Cases under age 40 years
CC 2,630 598 1.0
CT 159 51 1.4 0.04 [1.0–2.0 ]
TT 2 1 2.2 0.46 [0.2–23.7]
CT+TT 161 52 1.4 0.03 [1.0–1.9 ]
Total 2,791 650
Cases 41+ years
CC 2,630 2,441 1.0
CT 159 140 0.9 0.68 [0.8–1.2 ]
TT 2 10 5.4 0.02 [1.2–24.6]
CT+TT 161 150 1.0 0.97 [0.8–1.3 ]
Total 2,791 2,591
CI, confidence interval.Breast Cancer Research    Vol 7 No 6    Górski et al.
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ond allele. In one family with a germline BRCA2 mutation,
three cases of invasive breast cancer and one case of DCIS
were observed [13]. LOH at the BRCA2 locus was demon-
strated in all four cases. The authors suggest that DCIS and
LOH in the BRCA2 locus may be common early steps in the
development of invasive breast cancer in BRCA2 carriers. The
LOH data support the concept that BRCA2 behaves as a
tumor suppressor gene. In support of this hypothesis are our
observations of a greater breast cancer risk in women with two
inherited 5972T variants and a lower frequency of positive
family history among 5972C/T heterozygotes.
In our study, we observed no association between the exam-
ined variant and increased family history. This may be
explained by the modest association of the examined variant
with breast cancer risk and probable recessive pattern of
inheritance (the highest OR values were observed in homozy-
gotes, all of them with negative breast cancer family history).
Actually, at least some of the 5972C/T heterozygotes may be
compound heterozygotes, with the second allele being
another BRCA2 variant.
We now provide epidemiological and clinical evidence dem-
onstrating the deleterious nature of the C5972T allele. To our
knowledge, functional studies have not been performed on
this variant. Few other deleterious missense variants in
BRCA2 have been identified.
The HH genotype of the non-conservative amino acid substi-
tution polymorphism N372H in the BRCA2  gene was
reported to be associated with a 1.3-fold to 1.5-fold increase
in the risk of both breast and ovarian cancer [15-18], but there
have been negative studies as well [19,20].
Our control group was drawn both from the newborns of 10
Polish cities and from the adult population in the region of Szc-
zecin; however, the frequency of alleles was similar in the
newborn (5.7%) and adult (5.8%) populations. There was no
Table 2
Characteristics of breast cancers associated with 5972C/T or TT variants and wild-type BRCA2 sequence
5972C/T or TT Wild type ORa p-value 95% CI
N% N %
Histology
Medullary 7 6 122 7 0.86 0.71 [0.4–1.9]
Ductal 41 36 607 35 1.04 0.83 [0.7–1.5]
Tubular or tubulo-lobular 3 3 104 6 0.42 0.13 [0.1–1.3]
Lobular 22 19 364 21 0.90 0.70 [0.5–1.5]
DCIS+micro-invasion 22 19 121 7 3.18 <0.0001 [1.9–5.2]
Other 19 17 416 24 0.63 0.09 [0.4–1.0]
Multifocal 19 30 211 23 1.47 0.17 [0.8–2.6]
Bilateral 7 5 63 3 1.71 0.18 [0.7–3.8]
ER+ 50 67 586 62 1.24 0.40 [0.7–2.0]
Family history+b
All patients 32 21 569 26 0.72 0.14 [0.5–1.2]
Diagnosed at <40 years 4 10 97 24 0.36 0.06 [0.1–1.1]
00 0 p - v a l u e 9 5 %  C I
Mean age (years)c 43.9 44.4 0.5 0.34 [-0.5–1.5]
Mean tumor size (cm)c 2.0 2.1 0.1 0.41 [-0.1–0.3]
aOdds ratios (ORs) for individual variables represent the odds of being a mutation carrier for a woman with a particular characteristic, compared to 
all other women who did not have the characteristic. For histology the comparisons were made for one histological group to all other histologies. 
bFamily history+ indicates the occurrence of one or more breast or ovarian cancers among first and second degree relatives. cFor age and tumor 
size comparisons, p-values and confidence intervals refer to the difference of means. Data were missing from the following categories and these 
cases were excluded from the specific calculations: histology (909 cases), multi-focality (1,774 cases); bilaterality (744 cases), estrogen receptor 
status (1,746 cases), family history (756 cases), family history in group diagnosed <40 (150 cases). Patients who received neo-adjuvant 
chemotherapy were excluded from all analyses with the exception of family history. 184 patients with BRCA1 mutations were excluded from all 
analyses. ER+, estrogen receptor expression positive.Available online http://breast-cancer-research.com/content/7/6/R1023
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evidence that the genotype frequencies of the C5972T vari-
ants deviated from those expected from the Hardy-Weinberg
equilibrium for the combined control group (p = 0.79) or for
newborn and adult control groups (p = 0.59 and p = 0.73).
There was no statistical difference in the C5972T allele fre-
quencies in newborns recruited from the Szczecin metropoli-
tan region compared to other Polish cities (data not shown).
According to existing literature data, the frequency of the
C5972T variant is similar in other populations such as North
American, Austrian and Oceanian [6,7].
Conclusion
The heterozygosity of the BRCA2 C5972T variant appears to
be a neutral polymorphism in women above the age of 40 but
may be deleterious prior to age 40. The risk associated with
this allele was modest (OR = 1.4) in young women. Strong
associations were not observed until cases were subclassified
by their histological appearance or by homozygous state. It is
important to confirm these observations in other populations.
Large, well-controlled studies are needed to establish the full
range of risks associated with other BRCA2 alleles before
they can definitely be identified as neutral. Identification of
breast cancer susceptibility genes that are associated with
modest penetrance requires very large association studies,
unless the high-risk alleles are very common.
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